Drugs / Triamcinolone Hexacetonide
Triamcinolone Hexacetonide
also known as
Triamcinolonhexacetonid · Aristospan · Hexacetonide of triamcinolone · Kenalog · Lederspan · Triancil
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ARISTOSPAN | — | 1969-07-29 | fda.gov ↗ |
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials | ||||||
| Phase 3 | NCT03728478 | May 2019 → Feb 2025 overdue | oligoarticular juvenile idiopathic arthritis, rheumatoid factor-negative juvenile idiopathic arthritis | Gaslini Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT02381652 | Feb → Apr 2015 | osteoarthritis, knee | Anika Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01447160 | Oct 2011 → Apr 2012 | — | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05306548 | Apr 2022 → Mar 2027 expected | carpal tunnel syndrome | Diakonhjemmet Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02835521 | Aug 2016 → Feb 2017 | osteoarthritis, knee | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT02437461 | Apr 2015 → Sep 2017 | arthropathy | Uppsala University | Unknown | No outcome recorded |
| Phase 4 | NCT02102620 | Aug 2011 → Aug 2012 | osteoarthritis, hand | Federal University of São Paulo | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01026909 | Mar 2009 → Oct 2013 | Legg-Calve-Perthes disease | Seattle Children's Hospital | Terminated | No outcome recorded |
| — | NCT00840229 | Feb 2009 → Jun 2012 | frozen shoulder | Oslo University Hospital | Completed | No outcome recorded |
Also used as a comparator or background therapy in 18 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT03726788 Comparator | Sep 2019 → Nov 2021 | osteoarthritis, knee | Lille Catholic University | Withdrawn | No outcome recorded |
| Phase 2 | NCT03072381 Comparator | Jan 2017 → Oct 2020 | tendinosis | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT01770912 Comparator | Mar 2013 → Jan 2019 | — | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT00506896 Comparator | Jul 2004 → Jan 2006 | rheumatoid arthritis | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03390036 Comparator | Dec 2017 → Jul 2018 | osteoarthritis, knee | Anika Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03191903 Comparator | May 2017 → Apr 2018 | osteoarthritis, knee | Anika Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT06308887 Comparator | Oct 2023 → Feb 2024 | chronic pain syndrome, osteoarthritis, knee | Kastamonu University | Completed | No outcome recorded |
| Phase 4 | NCT04614311 Comparator | Dec 2020 → Nov 2024 | juvenile idiopathic arthritis | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03985280 Comparator | Jun 2018 → Jun 2020 | chronic pain syndrome | Jorge Orduña-Valls | Unknown | No outcome recorded |
| Phase 4 | NCT03086759 Comparator | Jan 2017 → Jun 2018 | osteoarthritis, knee | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 4 | NCT02829281 Comparator | Jul → Oct 2016 | osteoarthritis, knee | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT01824485 Background | Mar 2013 → Mar 2014 | osteoarthritis | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT05408065 Comparator | Nov 2022 → Sep 2026 expected | osteoarthritis | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
| — | NCT04824612 Background | Aug 2021 → Oct 2023 | keloid | University of Nove de Julho | Completed | No outcome recorded |
| — | NCT03804008 Comparator | Feb 2019 → Sep 2021 | plantar fasciitis | Aalborg University | Completed | No outcome recorded |
| — | NCT03535896 Background | Jun → Oct 2018 | plantar fasciitis | Aalborg University | Completed | No outcome recorded |
| — | NCT01851278 Comparator | Apr → Oct 2013 | rheumatoid arthritis | Federal University of São Paulo | Unknown | No outcome recorded |
| — | NCT00588354 Comparator | Oct 2006 → Feb 2009 | radiculopathy | Mayo Clinic | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 27 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triamcinolone hexacetonide | “Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of...” NCT03072381 ↗23“Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid...” NCT02381652 ↗ “Our objective is to evaluate what is the best dosage of viscosupplementation with hyaluronic acid (OSTEONIL®) associated with 1 ml (20 mg) of triamcinolone hexacetonide.” NCT01824485 ↗ “Effectiveness of Triamcinolone Hexacetonide Intra-articular Injection in Interphalangeal Joints: a 12 Weeks Randomized Controlled Trial in Osteoarthritis Hand Patients” NCT02102620 ↗ “intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide” NCT01447160 ↗ “Triamcinolone hexacetonide and methylprednisolone acetate doses depend on the affected joint.” NCT03728478 ↗ “we will administer 10 mg of bipuvacaine, and 40 mg triamcinolone hexacetonide.” NCT03985280 ↗ “Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection” NCT00506896 ↗ |
| Known as | Aristospan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01026909 ↗ |
| Known as | Hexacetonide of triamcinolone | “three applications of 1 ampoule of OSTEONIL®, one per week for three weeks + 1ml of Hexacetonide of triamcinolone only in the first injection.” NCT01824485 ↗ |
| Known as | Kenalog | “Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of...” NCT03072381 ↗ |
| Known as | Lederspan | “1 ml Triamcinolonhexacetonid (Lederspan, Meda)” NCT03535896 ↗ |
| Known as | Triamcinolonhexacetonid | “A 21-gauge, 40 mm needle is connected to a 2.5 cm3 syringe filled with 1 ml Triamcinolonhexacetonid 20mg/ml + 1 ml Lidocain 10 mg7ml.” NCT03804008 ↗1“1 ml Triamcinolonhexacetonid (Lederspan, Meda)” NCT03535896 ↗ |
| Known as | Triancil | “intralesional injection of 20 mg/ml triamcinolone hexacetonide (Triancil®, Apsen Farmacêutica S.A.)” NCT04824612 ↗ |
| Modality | Other / unclassified | “corticosteroid injection” NCT00840229 ↗ |
| Route | Other | “by intraarticular injection” NCT00506896 ↗ |